Canadian Semaglutide Sales Hit $3.5 Billion in 2025

Canadian sales of semaglutide medications including Ozempic and Wegovy reached approximately $3.5 billion in 2025, according to new data from IQVIA Canada.

Market Size Before Generic Competition

The $3.5 billion figure represents the total Canadian market for semaglutide products in 2025, establishing a baseline before generic manufacturers enter the market following patent expiration on January 4, 2026. IQVIA Canada, a leading healthcare data analytics company, provided this market assessment to CBC News.

The substantial sales volume demonstrates the significant financial impact that generic competition could have on both brand manufacturers and the broader pharmaceutical market in Canada. Health Canada is currently reviewing nine generic semaglutide applications from various manufacturers.

Generic Manufacturing Response

Multiple generic pharmaceutical companies are positioning to capture portions of this multi-billion dollar market. Vimy Pharma, a Canadian manufacturer, expects to file its generic semaglutide application with Health Canada in the coming weeks, joining eight other applications already under review.

Aspen Pharmacare has announced plans to enter the Canadian market with generic semaglutide by the third quarter of 2026. The company aims to leverage Canada's unique position as the only country where Novo Nordisk allowed its semaglutide patent to expire, creating opportunities for generic manufacturers.

Price Reduction Projections

Industry analysts project significant price reductions once generic versions reach Canadian pharmacy shelves. Current monthly costs for brand-name semaglutide products range between $300-$600 depending on the specific medication and dosage strength.

Healthcare economics expert Mina Tadrous estimates that three competing generic manufacturers could reduce prices to approximately $100 monthly from the current $400 for equivalent strength semaglutide products. Some production cost analyses suggest even lower manufacturing expenses, though final retail pricing will depend on market competition and distribution factors.

Healthcare System Impact

The substantial 2025 sales figures highlight the financial pressure that semaglutide medications have placed on both private insurance plans and individual patients paying out-of-pocket. Canadian employer drug plans have reported significant cost increases attributed to GLP-1 medication coverage.

Generic competition could alleviate some of these financial pressures while potentially expanding access to semaglutide treatments. Provincial health plans are monitoring Health Canada's generic approval process to determine future coverage decisions.

Healthcare providers and patients can track generic semaglutide development through our generic semaglutide tracker and explore current coverage options via our insurance coverage checker.

Market Timeline Expectations

While generic applications are under review, no generic semaglutide products have received Health Canada approval as of April 2026. The regulatory review process typically requires several months for completion, with most industry observers expecting initial approvals during summer 2026.

Production capabilities are already being established, with some generic manufacturers beginning production processes in Canadian facilities. This domestic production capacity could support rapid market entry once regulatory approvals are granted.

Additional information about generic semaglutide development and market access is available in our comprehensive FAQ section.

This article is for informational purposes only and does not constitute medical advice.